ES2017258A6 - Vaccine against melanoma - Google Patents

Vaccine against melanoma

Info

Publication number
ES2017258A6
ES2017258A6 ES8902106A ES8902106A ES2017258A6 ES 2017258 A6 ES2017258 A6 ES 2017258A6 ES 8902106 A ES8902106 A ES 8902106A ES 8902106 A ES8902106 A ES 8902106A ES 2017258 A6 ES2017258 A6 ES 2017258A6
Authority
ES
Spain
Prior art keywords
peptides
proteins
vaccine formulations
vaccine against
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8902106A
Other languages
Spanish (es)
Inventor
Joseph P Brown
Gregory Plowman
Karl E Hellstrom
Anthony Purchio
Sridhar Pennathur
Charles D Estin
Timothy M Rose
Hellstrom
Shiu-Lok Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26676698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2017258(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/007,230 external-priority patent/US5262177A/en
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of ES2017258A6 publication Critical patent/ES2017258A6/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Peptides or proteins which belong to a melanoma-associated antigen are described. These are prepared in large amounts using recombinant DNA techniques and/or chemical synthetic methods. The peptides or proteins can be used as immunogens in vaccine formulations which elicit an immune response able selectively to destroy melanoma cells in a vaccinated individual. When the peptides or proteins are expressed by a recombinant virus, it is possible to prepare vaccine formulations based on inactivated viruses or based on live viruses.
ES8902106A 1986-02-07 1989-06-15 Vaccine against melanoma Expired - Fee Related ES2017258A6 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82731386A 1986-02-07 1986-02-07
US07/007,230 US5262177A (en) 1986-02-07 1987-01-27 Recombinant viruses encoding the human melanoma-associated antigen

Publications (1)

Publication Number Publication Date
ES2017258A6 true ES2017258A6 (en) 1991-01-16

Family

ID=26676698

Family Applications (2)

Application Number Title Priority Date Filing Date
ES8700288A Expired - Fee Related ES2012815A6 (en) 1986-02-07 1987-02-06 Vaccine against melanoma
ES8902106A Expired - Fee Related ES2017258A6 (en) 1986-02-07 1989-06-15 Vaccine against melanoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES8700288A Expired - Fee Related ES2012815A6 (en) 1986-02-07 1987-02-06 Vaccine against melanoma

Country Status (18)

Country Link
JP (3) JP2664673B2 (en)
BE (1) BE1000175A3 (en)
CH (1) CH675424A5 (en)
DE (1) DE3703702C2 (en)
DK (1) DK63287A (en)
ES (2) ES2012815A6 (en)
FI (1) FI94836C (en)
GR (1) GR870195B (en)
HU (1) HU209144B (en)
IE (1) IE59597B1 (en)
IT (1) IT1222359B (en)
MX (1) MX9203574A (en)
NL (1) NL8700285A (en)
NO (1) NO178931C (en)
NZ (1) NZ219192A (en)
OA (1) OA08478A (en)
PT (1) PT84255B (en)
SE (2) SE506024C2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821925A1 (en) * 1998-05-15 1999-11-18 Roehnisch Tim Bacteriophage expression system for production of composition for induction of tumor specific responses
JP4414023B2 (en) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 Method and reagent for measuring arthritis-related melanotransferrin
JP4708027B2 (en) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Anti-cancer compositions and anti-infective disease compositions and methods of using them
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer

Also Published As

Publication number Publication date
SE8700466D0 (en) 1987-02-06
JP2664673B2 (en) 1997-10-15
DK63287A (en) 1987-08-08
NZ219192A (en) 1991-10-25
JPS62294698A (en) 1987-12-22
JPH08280390A (en) 1996-10-29
PT84255A (en) 1987-03-01
NO870475L (en) 1987-08-10
FI870501A0 (en) 1987-02-06
IE59597B1 (en) 1994-03-09
GR870195B (en) 1987-06-10
IT1222359B (en) 1990-09-05
NL8700285A (en) 1987-09-01
ES2012815A6 (en) 1990-04-16
FI94836C (en) 1995-11-10
NO870475D0 (en) 1987-02-06
SE8700466L (en) 1987-08-08
OA08478A (en) 1988-07-29
SE9202934D0 (en) 1992-10-07
FI94836B (en) 1995-07-31
MX9203574A (en) 1992-07-01
NO178931B (en) 1996-03-25
PT84255B (en) 1989-11-30
SE506024C2 (en) 1997-11-03
NO178931C (en) 1996-07-03
IT8719291A0 (en) 1987-02-06
IE870319L (en) 1987-08-07
FI870501L (en) 1987-08-08
BE1000175A3 (en) 1988-07-12
JPH09135692A (en) 1997-05-27
HU209144B (en) 1994-03-28
DE3703702A1 (en) 1988-02-18
HUT43107A (en) 1987-09-28
DE3703702C2 (en) 1997-07-10
DK63287D0 (en) 1987-02-06
CH675424A5 (en) 1990-09-28

Similar Documents

Publication Publication Date Title
UA42089C2 (en) Influenza vaccine based on envelope antigenic proteins of influenza virus, method for its production
ATE97164T1 (en) RECOMBINANT VACCINIA VIRUS MVA.
HU9500571D0 (en) Retro-, inverso-, and retro-inverso synthetic peptide analogues
EE9900343A (en) Synthetic Polynucleotide, Immune Response Method, Immunogenic Composition, Anti-HIV Immune Response Induction Method, Antigen-Inducing Cell Indication, and Pharmaceutical Composition
ATE295895T1 (en) GENETIC VACCINE AGAINST THE IMMUNO DEFICIENCY VIRUS
GB2303854B (en) Helicobacter proteins and vaccines
KR900700508A (en) Chimeric glycoprotein containing glycoprotein immune fragments against human respiratory syncytial virus
EA199800272A1 (en) FACTOR, STIMULATING DENDRIT CELLS
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
ATE101200T1 (en) VACCINES AGAINST HUMAN RESPIRATORY VIRUSES.
ATE73349T1 (en) HEPATITIS SURFACE ANTIGEN PARTICLE VACCINATION.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ATE344052T1 (en) PROTEIN DELIVERY SYSTEM USING PARTICLES SIMILAR TO HUMAN PAPILLOMA VIRUS.
ES2012815A6 (en) Vaccine against melanoma
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
ZA941853B (en) Stimulation of immune response by viral protein
DE69637435D1 (en) SAPONIN COMPOSITIONS AND ITS USE
DK204588D0 (en) HUMAN RHINOVIRUS PEPTIDES, PROCEDURES FOR THEIR PREPARATION AND VACCINES CONTAINING SUCH PEPTIDES
AR248047A1 (en) Vaccines based on modified bovine herpesvirus type i
TH11952A (en) Genetically modified marek's disease virus and vaccines?
RU92004487A (en) DNA, POLIPEPTID, VACCINE, VECTOR, MICROORGANISM, INSECTED CELL, REAGENT, METHODS OF TREATMENT AND PREVENTION, METHOD OF DETECTING ANTIGENES
ES8801958A1 (en) A PROCEDURE FOR THE DETERMINATION OF AIDS VIRUSES
WO2002078621A3 (en) Replication-competent recombinant virus and methods of use thereof

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20110614